Lynk Pharmaceuticals Co., Ltd, based in China, has announced the dosing of the first patient in a Phase III clinical study for its highly selective JAK1 inhibitor, LNK01001, aimed at treating atopic dermatitis (AD). This randomized, double-blind, placebo-controlled trial is designed to evaluate the efficacy and safety of LNK01001 in adult patients with moderate to severe AD in China, under the leadership of Professors Jianzhong Zhang and Cheng Zhou from the Department of Dermatology at Peking University People’s Hospital.
LNK01001 has previously completed three Phase II clinical studies targeting rheumatoid arthritis, ankylosing spondylitis, and atopic dermatitis. To date, the drug candidate has been administered to over 800 subjects globally, including approximately 100 participants in Phase I trials conducted in Australia and more than 700 patients in China, providing promising preliminary evidence of its efficacy and safety profile.- Flcube.com
